Our Approach: Sovereign AI & Federated Learning

Signed in as:

filler@godaddy.com

Account

The Sovereign Intelligence Model. We bring the questions to the data, so the data never has to leave home.

Digital glowing network globe with interconnected nodes and bright pathway.

Mission & Focus

Welcome to Regal Intel, where our sole focus as a **non-profit organization** is to accelerate the identification, development and accessibility of treatments for biotech and **rare and orphan diseases**. Our strategic regulatory AI-guidance is tailored for innovators, including non-profit companies, academic researchers, and consortia, working tirelessly within the rare disease ecosystem.

Our mission is to empower these efforts, facilitating the path for safe and effective therapies to reach underserved patient communities efficiently and sustainably.

Dedicated Regulatory AI-Expertise for BioTech and Rare Diseases

Our AI-based ecosystem has a proven track record helping organizations navigate highly complex regulatory pathways critical to this space. We provide a proactive, meticulous approach, driven by the urgency of patient need and focused on public benefit.

Expertise in Global Expedited Pathways

Orphan Drug Designation (ODD)
PRIME & Fast Track Designations
Breakthrough Therapy Designation
Humanitarian Device Exemption (HDE)
Pediatric Investigation Plans (PIPs)
EU, US, and key global market procedures

Our AI-based application provides a meticulous approach, sensitive to cost.

Supporting Complex and Rare Disease Therapies Innovation from Concept to Patient

Regal Intel's AI-driven ecosystem provides expert, non-profit guidance across the entire product lifecycle to navigate the complex journey of rare disease innovation. Our ecosystem supports the development and regulatory strategies for:

Critical diagnostic tools (biomarkers, assays) and targeted therapies (including vaccines, gene therapies, specialized biologics, and target enrichment) specifically for rare conditions.
Novel medical technologies, devices, or combination products uniquely suited to the needs of rare disease patients, including support for prototyping, testing, and assessing regulatory viability.
Appropriate advanced materials research and selection ensuring biocompatibility and suitability for specialized rare disease applications.
Development of robust Clinical Evaluation Reports (CERs) and Biological Evaluation Reports (BERs), adeptly addressing the challenges often associated with limited clinical data in rare populations through close collaboration with medical and scientific experts.

Our unwavering commitment is to facilitate the journey of effective and safe rare disease solutions from concept to the patients who urgently need them, ultimately improving outcomes and enhancing quality of life.

Connect With Us

Supporting Complex and Rare Disease Therapies

Innovation from Concept to Patient

Clinical trials for combination products require specialized expertise in integrating data from drug, device, and/or biologic components. Regal Intel assists with:

Clinical Trial Design: AI can be utilized to design clinical trial protocols that address the combined effects of components, helping to simulate outcomes and enable adaptive protocols.

Data Integration: We leverage AI to ensure seamless integration and analysis of data from different components. AI-powered systems from Regal Technology Partners can also be used to collect and analyze a vast amount of data from clinical trials, reducing human error and uncovering actionable insights.

Post-Market Surveillance (PMS): We develop and implement integrated pharmacovigilance systems tailored to the unique needs of combination products. Our AI-powered PMS software can automate complaint handling, perform trend analysis, and actively monitor for potentially reportable events, thereby ensuring patient safety and product quality.

Targeted Therapies & Diagnostics

Preparing comprehensive regulatory submissions for combination products requires meticulous attention to detail and integrated documentation. Regal Intel assists with:

Integrated Regulatory Dossier Preparation (NDA, PMA, BLA, etc.): Ensuring all components are thoroughly documented.

eCTD Submissions: Streamlining the submission process with electronic common technical documents.

Labeling and Packaging Compliance: Meeting specific regulatory guidelines for combination products.

Risk Management and Mitigation: Developing and implementing strategies to mitigate risks associated with combination products through the expertise of Regal Technology Partners.

Novel Medical Technologies

Maintaining ongoing safety and efficacy monitoring is crucial for combination products. Regal Intel provides: Integrated Pharmacovigilance Systems tailored to the unique needs of combination products. Adverse Event Reporting and Signal Detection, ensuring monitoring and reporting of adverse events across all components. Risk Management Plans focused on developing and implementing strategies to mitigate risks. Post-Market Clinical Follow-up Studies that guarantee long-term safety and efficacy, supported by Regal Technology Partners.

Materials & Biocompatibility

Regal Intel possesses the expertise to help navigate the regulatory landscape for constituent parts of combination products. This includes expertise in: Device constituent parts: Assisting with the regulatory requirements for the device components of combination products, including device classification, risk assessment, and compliance with relevant standards (ISO 13485, etc.). Drug constituent parts: Navigating the regulatory requirements for the drug components of combination products, including CMC, preclinical, and clinical data requirements, and compliance with cGMP. Biologic constituent parts: Assisting with regulatory requirements for biologic components of combination products, including BLA submissions, cell and tissue requirements, and other related regulatory matters, in collaboration with Regal Technology Partners.

Clinical Evaluation & Reports

At Regal Intel, we specialize in the development of robust Clinical Evaluation Reports (CERs) and Biological Evaluation Reports (BERs), effectively addressing the challenges posed by limited clinical data through our expertise in Regal Intel and collaboration with Regal Technology Partners.